Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	131.99	1,446	1,024	1,181	629.06
Short-Term Investments	264.32	376.22	228.89	222.53	137.46
Trading Asset Securities	224.87	105.65	210.82	2.21	5.87
Cash & Short-Term Investments	621.19	1,928	1,464	1,406	772.38
Cash Growth	-67.78%	31.74%	4.13%	82.00%	81.09%
Accounts Receivable	116.29	218.83	104.28	142.44	141.75
Other Receivables	-	80.66	66.13	22.46	20.32
Receivables	116.29	299.53	170.44	166.58	164.49
Inventory	31.1	53.35	59.94	44.36	31.75
Prepaid Expenses	-	1.99	2.13	5.48	3.68
Restricted Cash	17.92	33.07	27.2	1.44	7.47
Other Current Assets	48.49	36.91	41.53	15.49	13.41
Total Current Assets	834.98	2,353	1,765	1,639	993.17
Property, Plant & Equipment	595.62	728.73	624.67	486.91	379.23
Long-Term Investments	3,790	85.41	16.03	18.47	13.99
Goodwill	1.34	1.36	2.55	14.15	14.12
Other Intangible Assets	13.04	18.65	23.81	26.42	26.02
Long-Term Accounts Receivable	-	0.29	0.4	-	-
Long-Term Deferred Tax Assets	27.74	16.51	15.05	5.09	3.7
Other Long-Term Assets	15.81	183.26	98.93	43.77	17.17
Total Assets	5,278	3,387	2,546	2,234	1,447
Accounts Payable	29.84	39.96	55.76	30.18	23.38
Accrued Expenses	69.86	164.77	210.03	156.11	114.4
Short-Term Debt	88.75	56.94	33.23	-	44.06
Current Portion of Long-Term Debt	-	0.07	0.45	0.52	0.58
Current Portion of Leases	7.52	8.87	11.1	7.51	2.59
Current Income Taxes Payable	9.39	18.13	16.15	15.72	3.53
Current Unearned Revenue	47.36	98.58	44.33	35.47	84.79
Other Current Liabilities	54.63	107.49	174.93	167.79	54.58
Total Current Liabilities	307.34	494.81	545.98	413.31	327.91
Long-Term Debt	570.48	712.72	567.23	381.86	1.26
Long-Term Leases	56.99	63.91	44.01	27.35	6.51
Long-Term Unearned Revenue	-	47.96	2.01	15.54	288.55
Long-Term Deferred Tax Liabilities	5.84	5.62	8.01	7.73	7.03
Other Long-Term Liabilities	14.26	17.93	16.48	0.4	0.55
Total Liabilities	954.91	1,343	1,184	846.18	631.82
Common Stock	2.14	2.12	2.11	2.1	1.95
Additional Paid-In Capital	1,982	1,939	1,473	1,274	1,067
Retained Earnings	-	-597.73	-502.25	-275.4	-175.01
Treasury Stock	-6.09	-9.45	-11.92	-15.75	-16.71
Comprehensive Income & Other	2,344	56.87	49.57	60.78	24.92
Total Common Equity	4,321	1,391	1,011	1,046	901.71
Minority Interest	2.19	653.28	352.13	341.7	-86.11
Shareholders' Equity	4,323	2,044	1,363	1,388	815.59
Total Liabilities & Equity	5,278	3,387	2,546	2,234	1,447
Total Debt	723.74	842.5	656.02	417.24	55
Net Cash (Debt)	-102.55	1,086	807.69	988.47	717.38
Net Cash Growth	-	34.43%	-18.29%	37.79%	78.28%
Net Cash Per Share	-0.05	0.51	0.39	0.49	0.38
Filing Date Shares Outstanding	2,121	2,124	2,111	2,096	1,953
Total Common Shares Outstanding	2,121	2,123	2,111	2,096	1,953
Working Capital	527.64	1,858	1,219	1,226	665.26
Book Value Per Share	2.04	0.66	0.48	0.50	0.46
Tangible Book Value	4,307	1,371	984.18	1,005	861.57
Tangible Book Value Per Share	2.03	0.65	0.47	0.48	0.44
Land	320.67	350.49	265.52	188.58	175.82
Machinery	311.68	319.62	257.2	224.78	184.07
Construction In Progress	129.37	131.6	142.06	91.22	66.44
Order Backlog	-	-	-	-	94.7

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.